Schrödinger Q1 2026: Cost Savings Show Early Traction, but Software Growth Visibility Remains Limited

What happened

Schrödinger’s Q1 2026 results offer the first operational read on the restructuring and clinical phase-out that began in mid-2025. Operating expenses fell year-over-year, contributing to a notable reduction in quarterly cash burn, indicating the ~$70 million savings plan is on track. Software revenue growth remained modest, reflecting the pharma budget headwinds that forced a guidance cut last year, with no clear evidence of accelerating scale-ups yet. The company’s liquidity buffer stays above $400 million, but the $241 million ATM overhang continues to cap upside conviction. Overall, the quarter supports a stabilization narrative, but the core thesis—renewal-season expansion in Q2—remains unvalidated.

Implication

Sustained cost discipline lowers the probability of near-term dilution, a positive counterbalance to sluggish software growth. However, the bull case depends on Q2’s renewal outcomes—if ≥$5M ACV customers increase and FY2026 software guidance re-accelerates above 10%, the stock could re-rate toward $14. Failure to deliver would reinforce the bear case of stalled enterprise adoption, with downside to $8.

Thesis delta

The Q1 results partially de-risk the thesis by demonstrating cost-out execution, but software growth visibility remains unchanged; the investment debate now fundamentally centers on Q2 renewal-scale-up evidence rather than Q1 performance.